In an interview with NPR released today, retired Supreme Court Justice John Paul Stevens came out in support for marijuana legalization.
When asked if he believed the federal government should legalize marijuana, the 94 year old former Justice replied:
“Yes, I really think that that’s another instance of public opinion [that's] changed. And recognize that the distinction between marijuana and alcoholic beverages is really not much of a distinction. Alcohol, the prohibition against selling and dispensing alcoholic beverages has I think been generally, there’s a general consensus that it was not worth the cost. And I think really in time that will be the general consensus with respect to this particular drug.”
You can listen to the full interview from National Public Radio here.
Stevens joins the majority of Americans who are ready to see an end to our war on marijuana consumers and for the country to move towards a system of legalization and regulation.
Dear NORML members and supporters,
As always, there will be large public gatherings all around America (and other countries too) to celebrate the responsible adult use of cannabis. The day is a cultural phenomenon, with both substantial media output (some entire cable networks broadcast cannabis-centric programming and entertainment–like Comedy Central) and coverage of public celebrations (cities like Denver expect downtown public pot celebrations drawing 80,000 or more Saturday and Sunday).
The patchwork of cannabis law enforcement in this country is so disparate that in some locations the gatherings will celebrate their appreciation of the herb, but under harsh threat of arrest and criminal sanctions. Contrastingly, in other parts of the country, where I write this letter from, the city of Denver–where I’ve paid an effective 35% tax rate on the retail purchase of a small amount of a strain called ‘Tangie’, and where over 40,000 attendees are expected for High Times’ Cannabis Cup Awards–the events here are decidedly in celebration of the only place currently on earth where an adult can purchase and legally consume cannabis in a similar manner to that of alcohol products.
By July of this year, the citizens and visitors to Washington State will enjoy the same freedoms and responsibilities when their cannabis retail market officially commences.
Two down, forty-eight more states and territories to go…
For over a dozen years NORML has had unique 4/20 fundraisers, promoting an annual membership* for as low as $4.20, and this year is no different. Hats off to legalization–upgrade your membership for $42 and get a limited edition hemp hat* from Grassroots California.
With Alaska and Oregon voters likely propelling their states to join Colorado and Washington this election season via binding voter initiatives, we will all have even more to rejoice (and consumer choices for safe, affordable, legal and taxed cannabis) next April 20th.
Thank you for supporting NORML’s long standing public advocacy efforts to end cannabis prohibition and replace it with a far more rational and responsible public policy that has sustained the organization to this day–when I’m reporting to you the first legal and taxed cannabis purchase in my lifetime.
Allen St. Pierre
* NORML 420 membership offer is valid until 4/20/14 at 11:59pm EST. (Limited quantity of hemp hats)
Tampa, FL – On Sunday April 13th, people came from all parts of the sunshine state to the to attend the first statewide Florida NORML conference at the University of South Florida. While the most critical topic of the day was Question 2 (Florida’s medical marijuana ballot initiative) to be voted on in the November election, there was also a diverse range of information presented by conference speakers such as student rights on campus, organizing and social media outreach.
Panelists consisted of a group of nationally recognized advocates and some of the state’s most high profile reformers. They included federal medical marijuana patient Irv Rosenfeld, Kathy Jordan of the Kathy Jordan Medical Marijuana Act, the Silver Tour’s Robert Platshorn and Florida NORML Chapter Director Karen Goldstein. Other speakers included Catherine Sevcenko, litigation coordinator for the Foundation for Individual Rights in Education (FIRE) and Eli Zucker, Founding Director of USF NORML and Sabrina Fendrick of National NORML.
The event was organized and hosted by the USF NORML chapter, with support from Students for Liberty and United for Care – the campaign behind Question 2. For more information in how to get involved with marijuana law reform in the sunshine state, please contact Karen Goldstein at firstname.lastname@example.org.
Lawmakers in Alabama and Utah recently approved legislation seeking to authorize the physician-supervised use of varieties of cannabis and/or extracts high in the non-psychotropic cannabinoid cannabidiol (CBD). Both measures, which I previously summarized as ‘largely unworkable,‘ have now been signed into law.
In recent days, lawmakers in three additional states — Kentucky, Mississippi, and Wisconsin — have similarly signed off on CBD-explicit legislation. These measures are now awaiting signatures from each states’ respective Governors.
Similar to Alabama’s SB 174 (aka ‘Carley’s Law), which only permits the use of CBD by prescription during the course of an FDA-approved clinical trial, the pending Kentucky and Wisconsin bills may also be classified as ‘research-centric’ measures. Kentucky’s SB 124 permits physicians “practicing at a hospital or associated clinic affiliated with a Kentucky public university” to “dispense” cannabidiol during the course of an FDA-approved clinical trial. Wisconsin’s AB 726 similarly limits those who may legally dispense CBD to only include those physicians who have obtained an FDA-issued investigational drug permit to prescribe it. In Tennessee, lawmakers are also close to finalizing similar language (included in HB 2461 and SB 2531) that seeks to allow university clinical researchers to “manufacture” and “dispense” high-CBD cannabis oil “as part of a clinical research study on the treatment of intractable seizures.” (By contrast, separate, broader medical cannabis measures seeking to authorize the use of the whole plant failed this year in all three states.)
As I’ve previously written here and here, it is unlikely that specific changes in state law will stimulate these type of proposed clinical trials from taking place in these states any time soon. Because CBD is acknowledged by federal regulators to be classified as a schedule I prohibited substance, multiple federal agencies — including the FDA, DEA, NIDA (US National Institute of Drug Abuse), and PHS (Public Health Service) must all sign off on any clinical investigation of the cannabinoid — a process that typically takes several years. A keyword search of FDA-approved clinical trials using the terms “cannabidiol” and “United States” yields fewer than ten ongoing human trials involving CBD — less than half of which are assessing its potential therapeutic application. (Two additional safety trials assessing the use of GW Pharmaceutical’s patented high-CBD formulation Epidiolex in children with severe epilepsy are also ongoing.)
Unlike the above-mentioned measures, Mississippi’s HB 1231, does not seek to encourage state-sponsored clinical trials. Rather, the measure exempts specific high-CBD formulated oils “that contain more than fifteen percent cannabidiol [and] … no more than one-half of one percent of tetrahydrocannabinol” from the state’s definition of a schedule I prohibited substance. However, like Utah’s HB 105 (aka ‘Charlee’s Law), Mississippi’s pending law does not provide guidance as to where patients could legally obtain such extracts. Though such high-CBD products are presently available in a limited number of medical cannabis states (such as in California and Colorado), these extracts are typically only available to in-state residents who possess authorization from a physician licensed to practice in that state. (Although Colorado state law also allows for a recreational cannabis market, which may be legally accessed by out-of-state residents, at present time such high-CBD concentrates are seldom available at retail outlets.)
Additional cannabidiol-specific measures also remain pending in Florida and South Carolina, among other states. NORML will report on these measures as they progress and we will continue to express caution in regards to their practical utility for those patients who require immediate access to whole-plant cannabis and its variety of naturally-occurring compounds.
Today, the Maryland House of Delegates voted 78 to 55 in favor of Senate Bill 364 which reduces the penalty for possession of 10 grams or less of marijuana from a criminal misdemeanor to a civil offense.
Senate Bill 364 was originally amended by the House Judiciary Committee to simply form a task force to study the issue of marijuana decriminalization. However, this morning, under pressure from the House Black Caucus, the House Judiciary Committee reversed their vote and instead voted 13 to 8 to approve an amended version of SB 364. As amended by committee, the bill would make possession of 10 grams or less a civil offense with the first offense punishable by a $100. The fine for a second offense would be $250, and the fine for a third and subsequent offenses would be $500. The original Senate version set the fine at $100, no matter which offense it was. SB 364 is now expected to go to conference committee to resolve the differences between the version approved by the House and the one approved by the state Senate.
Commenting on today’s vote, NORML Communication Director Erik Altieri stated, “This bill represents a great step forward in reversing the devastating effect current marijuana policies have on communities in Maryland. While the state must now move forward on the legalization and regulation of marijuana, we applaud Maryland legislators in taking action to end the 23,000 marijuana possession arrests occurring in the state every year.”
According to a 2013 ACLU report, Maryland possesses the fourth highest rate of marijuana possession arrests per capita of any state in the country. Maryland arrests over 23,000 individuals for simple marijuana possession every year, at the cost over of 100 million dollars.
NORML will keep you updated on the progress of this legislation.